Q1 2025 H Lundbeck A/S Earnings Call Transcript
Key Points
- H. Lundbeck AS (HLUBF) reported a strong revenue growth of 16% in Q1 2025, with strategic brands growing by 24%.
- The company’s key growth drivers, Vyepti and Rexulti, saw significant growth rates of 62% and 28%, respectively.
- The company is advancing its innovative pipeline, particularly in neuro-specialty and neuro-rare areas, with promising progress in phase III trials.
- H. Lundbeck AS (HLUBF) raised its full-year guidance, expecting revenue growth between 8% and 11% at constant exchange rates.
- The company achieved an adjusted EBITDA margin expansion to 34.9%, reflecting strong operational leverage and disciplined resource allocation.
- The company faces anticipated loss of exclusivity on some strategic brands, including Trintellix, which is expected to face generic entry in Canada.
- There is a potential delay in the launch of Brexpiprazole for PTSD due to postponed FDA advisory committee meetings.
- H. Lundbeck AS (HLUBF) reported higher financial expenses due to the acquisition of Longboard and unfavorable currency effects.
- The company expects further erosion in its mature brand portfolio, projecting a mid-single digit revenue decline.
- There is uncertainty regarding the impact of macroeconomic factors, such as tariffs, on the company's financial performance.
Ladies and gentlemen, welcome to the Lundbeck A/S financial statement for the first three months of the 2025 conference call. I am Sandra, the chorus call operator.
I would like to remind you that all participants have been listening on the mode and the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Charl Van Zyl, President and CEO. Please go ahead, sir.
/- -
So welcome everybody to the Lundbeck earnings call for quarter one 2025. From the outset, I want to just make a quick statement to say again, these strong results of the first quarter are really serving as another proof point of the path we are on in terms of a focused innovative strategy, confirming very much that the path is very strong for us going forward.
So let's go to the next slide, please. Of course, what we discussed today are forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
